You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Niraparib

Showing 1 - 25 of 186
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Trial in Beijing (Niraparib)

Recruiting
  • Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
  • Niraparib
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Nov 15, 2023

Recurrent Glioblastoma Trial (Niraparib, Re-irradiation (re-RT))

Not yet recruiting
  • Recurrent Glioblastoma
  • Niraparib
  • Re-irradiation (re-RT)
  • (no location specified)
Dec 23, 2022

Thrombocytopenia Trial (Hetrombopag)

Not yet recruiting
  • Thrombocytopenia
  • (no location specified)
Sep 7, 2023

Ovarian Tumors Trial in Nanjing (Niraparib)

Completed
  • Ovarian Neoplasms
  • Niraparib
  • Nanjing, China
    Zhongda hospital
Feb 17, 2023

Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jan 5, 2023

Safety of Niraparib in Korean Primary and Recurrent Epithelial

Completed
  • Epithelial Ovarian Cancer
  • Niraparib
  • Seoul, Korea, Republic of
    Department of Obstetrics and Gynecology, University of Ulsan Col
Oct 11, 2023

Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer Trial in Toronto (Niraparib)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • Niraparib
  • Toronto, Ontario, Canada
    Sunnybrook Research Institute
Jul 18, 2023

Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma Trial in Boston (Niraparib, Resection/Treatment with Niraparib)

Recruiting
  • Low-grade Glioma
  • +4 more
  • Niraparib
  • Resection/Treatment with Niraparib
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 19, 2022

Head and Neck Squamous Cell Carcinoma Trial in Spain (Dostarlimab, Niraparib, cisplatin plus radiotherapy)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Badalona, Cataluña, Spain
  • +4 more
Mar 13, 2023

Ovarian Cancer in Expanded Access Program in Latin America

Not yet recruiting
  • Ovarian Cancer
  • Observational study
  • (no location specified)
May 4, 2023

Head Neck Cancer Trial in Cincinnati, Columbus (Niraparib, Dostarlimab)

Active, not recruiting
  • Head and Neck Cancer
  • Cincinnati, Ohio
    University of Cincinnati Medical Center
Jan 31, 2023

Brain Metastases Trial in Houston (Niraparib, Dostarlimab)

Not yet recruiting
  • Brain Metastases
  • Houston, Texas
    M D Anderson Cancer Center
Jan 17, 2023

A Real-World Patient-Reported Outcomes Study in Long-Term Use of

Recruiting
  • Ovarian Cancer
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Sep 13, 2023

    Ovarian Cancer Recurrent Trial in Sutton, London (Niraparib oral capsule, SBRT)

    Not yet recruiting
    • Ovarian Cancer Recurrent
    • Niraparib oral capsule
    • SBRT
    • Sutton, Surrey, United Kingdom
    • +1 more
    Aug 10, 2023

    Endometrial Cancer, Serous Adenocarcinoma, Uterine Tumor Trial (Niraparib oral capsule)

    Not yet recruiting
    • Endometrial Cancer
    • +2 more
    • Niraparib oral capsule
    • (no location specified)
    Oct 31, 2022

    Tumors Trial in United States (GSK4524101, Niraparib)

    Not yet recruiting
    • Neoplasms
    • San Francisco, California
    • +5 more
    Oct 5, 2023

    Niraparib in Patients With Ovarian Cancer in Clinical Practice

    Recruiting
    • Ovarian Cancer
    • Niraparib
    • Tokyo, Japan
      Takeda Selected Site
    Oct 21, 2022

    Metastatic Castration-resistant Prostate Cancer Trial (Niraparib plus Abiraterone Acetate (Nira/AA) combination,

    Available
    • Metastatic Castration-resistant Prostate Cancer
    • (no location specified)
    Aug 24, 2022

    Ovarian Cancer Trial

    Not yet recruiting
    • Ovarian Cancer
      • (no location specified)
      Oct 13, 2022

      Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma Trial in Gainesville, Miami, Orlando (Niraparib)

      Completed
      • Mesothelioma
      • +3 more
      • Niraparib
      • Gainesville, Florida
      • +2 more
      Jan 4, 2023

      Mesothelioma, Malignant Trial in Leicester (Niraparib Oral Product, Active Symptom Control)

      Recruiting
      • Mesothelioma, Malignant
      • Niraparib Oral Product
      • Active Symptom Control
      • Leicester, United Kingdom
        University Hospitals of Leicester NHS Trust, Royal Leicester Inf
      Jul 20, 2022

      Ovarian Cancer Trial in Chengdu (Yangzheng Xiaoji, Niraparib)

      Not yet recruiting
      • Ovarian Cancer
      • Yangzheng Xiaoji
      • Niraparib
      • Chengdu, Sichuan, China
        Sicchuan cancer hospital
      Nov 30, 2022

      Advanced Solid Tumor, Ovarian Cancer Trial in Richmond (Neratinib 160 mg, Neratinib 200 mg, Neratinib 240 mg)

      Recruiting
      • Advanced Solid Tumor
      • Ovarian Cancer
      • Neratinib 160 mg
      • +7 more
      • Richmond, Virginia
        Virginia Commonwealth University
      May 6, 2022

      Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

      Not yet recruiting
      • Platinum-Resistant Fallopian Tube Carcinoma
      • +5 more
      • Biopsy
      • +4 more
      • Duarte, California
        City of Hope Medical Center
      Jan 3, 2023

      ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Sacramento (Niraparib, Niraparib Tosylate Monohydrate,

      Recruiting
      • ATM Gene Mutation
      • +16 more
      • Niraparib
      • +2 more
      • Sacramento, California
        University of California Davis Comprehensive Cancer Center
      Oct 27, 2022